Recombinant human activated protein C in sepsis: Previous concerns and current usage

Therapy

Volumn 1, Issue 1, 2004, Pages 123-129

  Haley, Michael ^a   Cui, Xizhong ^a   Minneci, Peter C ^a   Deans, Katherine J ^a   Natanson, Charles ^a   Eichacker, Peter Q ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Activated protein C; Cost effectiveness; Sepsis; Therapy

Indexed keywords

ANTITHROMBIN III; BRADYKININ ANTAGONIST; CORTICOSTEROID DERIVATIVE; DROTRECOGIN; HEPARIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROSTAGLANDIN INHIBITOR; PROTEIN C; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BLEEDING DISORDER; BRAIN HEMORRHAGE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; LOW DRUG DOSE; META ANALYSIS; MORTALITY; POSTMARKETING SURVEILLANCE; REVIEW; SEPSIS; THROMBOSIS; TREATMENT OUTCOME;

EID: 14544272387     PISSN: 14750708     EISSN: None     Source Type: Journal    
DOI: 10.1586/14750708.1.1.123     Document Type: Review

References (22)

1. Bernard GR, Vincent JL, Laterre PF et al.: Efficacy and safety of human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699-709 (2001).
2. Matthay M: Severe sepsis - a new treatment with both anticoagulant and anti-inflammatory properties. N. Engl J. Med. 344, 759-762 (2001).
3. Okie S: New treatment found to cut sepsis deaths. The Washington Post. 10, A2 (2001).
4. Warren S, Suffredini A, Eichacker PQ, Mumford R: Risks and benefits of activated protein C treatment for severe sepsis. N. Engl. J. Med. 347, 1027-1030 (2002).
5. Warren BL, Eid A, Singer P et al.: (for the KyberSept Trial Study Group). High-dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA 286, 1869-1878 (2001).
6. Abraham E, Reinhart K, Svoboda P: Assessment of thee safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. JAMA 290(2), 238-247 (2003).
7. Joyce DE, Grinnell BW: Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kB. Crit. Care Med. 30, S288-S293 (2002).
8. Derhaschnig U, Reiter R, Knobl P et al.: Recombinant human-activated protein C (rhAPC; drotrecogin α [activated]) has minimal effect on markers of coagulation, fibrinolysis and inflammation in acute human endotoxemia. Blood 102, 2093-2098 (2003).
9. Gordan B: ENHANCE: Worldwide trial results on the efficacy and safety of activated protein C. 6th World Congress on Trauma, Shock, Inflammation and Sepsis. Munich, Germany, (2004).
10. Eichacker PQ, Parent C, Kalil A et al.: Risk and efficacy of anti-inflammatory agents: retrospective and confirmatory studies of sepsis. Am. J. Respir. Crit. Care Med. 166, 1197-1205 (2002).
11. Eichacker PQ, Natanson C: Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action and safety concerns resulted in labeling restrictions and the need for Phase IV trials. Crit. Care Med. 31(Suppl. 1), S94-S96 (2003).
12. Angus DC, Linde-Zwirble WT, Clermont G et al.: Cost-effectiveness of drotrecogin a (activated) in the treatment of severe sepsis. Crit. Care Med. 31(1), 1-11 (2003).
13. Banks SM, Gerstenberger E, Eichacker PQ, Natanson C: Long-term cost effectiveness of drotecogin a (activated): an unanswered question. Crit. Care Med. 31(1), 308-309 (2003).
14. Manns BJ, Lee H, Doig CJ, Johnson D and Donaldson C: An economic evaluation of activated protein C treatment for severe sepis. N. Engl J. Med. 347(13), 993-1000 (2002).
15. Rose JC, Unis AS: A mortality index for postmarketing surveillance of new medications. Am. J. Emerg. Med. 18(2), 176-179 (2000).
16. Edwards IR: Safety monitoring of new antimalarials in immediate post-marketing phase. Med. Trop. 58(Suppl. 3), 93-96 (1998).
17. Westerholm B: The rationale for a post-marketing surveillance. Hum. Reprod. 2(1), 41-44 (1987).
18. Tanzi M: Use of drotrecogin α (activated) (Xigris™) for the treatment of severe sepsis - medical use evaluation by Novation. April (2003).
19. Davidson BL, Geert WH, Lensing AW: Low-dose heparin for severe sepsis. N. Engl J. Med. 347(13), 1036-1037 (2002).
20. Goldhaber SZ: PREVENT (PRospective EValuation of Dalteparin Efficacy in Immobilized PantieNts Trial) trial. 32nd Critical Care Congress. San Antonio, TX, USA, (2003).
21. Chadda K, Annane D: The use of corticosteroids in severe sepsis and acute respiratory distress syndrome. Ann. Med. 34(7-8), 582-589 (2003).
22. Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C: Dose-dependent effects of steroids on survival rates and shock during sepsis: a metaanalysis. Ann. Int. Med. To be published 6 July (2004).